BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

491 related articles for article (PubMed ID: 19402771)

  • 1. Sugammadex: a selective relaxant binding agent for reversal of neuromuscular block.
    Hogg RM; Mirakhur RK
    Expert Rev Neurother; 2009 May; 9(5):599-608. PubMed ID: 19402771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of neuromuscular block with a selective relaxant-binding agent: sugammadex.
    Ren WH; Jahr JS
    Am J Ther; 2009; 16(4):295-9. PubMed ID: 19535969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuromuscular transmission: new concepts and agents.
    de Boer HD
    J Crit Care; 2009 Mar; 24(1):36-42. PubMed ID: 19272537
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sugammadex: the first selective binding reversal agent for neuromuscular block.
    Kovac AL
    J Clin Anesth; 2009 Sep; 21(6):444-53. PubMed ID: 19833281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sugammadex: a novel agent for the reversal of neuromuscular blockade.
    Nicholson WT; Sprung J; Jankowski CJ
    Pharmacotherapy; 2007 Aug; 27(8):1181-8. PubMed ID: 17655516
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cochrane corner: sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
    Abrishami A; Ho J; Wong J; Yin L; Chung F
    Anesth Analg; 2010 Apr; 110(4):1239. PubMed ID: 20357160
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical implications of sugammadex.
    Caldwell JE; Miller RD
    Anaesthesia; 2009 Mar; 64 Suppl 1():66-72. PubMed ID: 19222433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel approach to reversal of neuromuscular blockade.
    Della Rocca G; Pompei L
    Minerva Anestesiol; 2009 May; 75(5):349-51. PubMed ID: 19412157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical pharmacology of sugammadex.
    Bom A; Hope F; Rutherford S; Thomson K
    J Crit Care; 2009 Mar; 24(1):29-35. PubMed ID: 19272536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial.
    Khuenl-Brady KS; Wattwil M; Vanacker BF; Lora-Tamayo JI; Rietbergen H; Alvarez-Gómez JA
    Anesth Analg; 2010 Jan; 110(1):64-73. PubMed ID: 19713265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sugammadex in clinical practice.
    Mirakhur RK
    Anaesthesia; 2009 Mar; 64 Suppl 1():45-54. PubMed ID: 19222431
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sugammadex: another milestone in clinical neuromuscular pharmacology.
    Naguib M
    Anesth Analg; 2007 Mar; 104(3):575-81. PubMed ID: 17312211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversal of rocuronium-induced profound neuromuscular block by sugammadex in Duchenne muscular dystrophy.
    de Boer HD; van Esmond J; Booij LH; Driessen JJ
    Paediatr Anaesth; 2009 Dec; 19(12):1226-8. PubMed ID: 19863737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: a multicenter, dose-finding and safety study.
    de Boer HD; Driessen JJ; Marcus MA; Kerkkamp H; Heeringa M; Klimek M
    Anesthesiology; 2007 Aug; 107(2):239-44. PubMed ID: 17667567
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine.
    Sacan O; White PF; Tufanogullari B; Klein K
    Anesth Analg; 2007 Mar; 104(3):569-74. PubMed ID: 17312210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial.
    Blobner M; Eriksson LI; Scholz J; Motsch J; Della Rocca G; Prins ME
    Eur J Anaesthesiol; 2010 Oct; 27(10):874-81. PubMed ID: 20683334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sugammadex: a novel approach to reversal of neuromuscular blockade.
    Aniskevich S; Leone BJ; Brull SJ
    Expert Rev Neurother; 2011 Feb; 11(2):185-98. PubMed ID: 21306205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective relaxant binding agents for reversal of neuromuscular blockade.
    Bom A; Epemolu O; Hope F; Rutherford S; Thomson K
    Curr Opin Pharmacol; 2007 Jun; 7(3):298-302. PubMed ID: 17368102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical pharmacology and efficacy of sugammadex in the reversal of neuromuscular blockade.
    Schaller SJ; Lewald H
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1097-108. PubMed ID: 27463265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New drug sugammadex: a selective relaxant binding agent.
    Welliver M
    AANA J; 2006 Oct; 74(5):357-63. PubMed ID: 17048555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.